The use of mobile phone data to inform analysis of COVID-19 pandemic epidemiology

Grantz, Kyra H.; Meredith, Hannah R.; Cummings, Derek A. T.; Metcalf, C. Jessica E.; Grenfell, Bryan T.; Giles, J. R.; Mehta, Shruti H.; Solomon, Sunil S.; Labrique, Alain; Kishore, Nishant; Buckee, Caroline O.; Wesolowski, Amy

doi:10.1038/s41467-020-18190-5

Cited by 331 publications

(297 citation statements)

References 45 publications

Supporting

Mentioning

294

Contrasting

Unclassified

Order By: Relevance

“…The second instead, the topic and references. Category Topic and references Non-pharmaceutical interventions Effectiveness of NPIs [36] , [349] , [350] , [351] , [352] ; Effects of NPIs [353] , [354] , [355] , [356] , [357] ; Epidemic modeling [358] Change in medical practice Surgery [34] , [359] ; Ophthalmology [35] ; Disease control [360] ; Dentistry [361] Adoption of NPIs [362] , [363] Impact of digital technology [364] , [365] …”

Section: Reviewsmentioning

confidence: 99%

See 1 more Smart Citation

Non-pharmaceutical interventions during the COVID-19 pandemic: A review

2021

View full text Add to dashboard Cite

Infectious diseases and human behavior are intertwined. On one side, our movements and interactions are the engines of transmission. On the other, the unfolding of viruses might induce changes to our daily activities. While intuitive, our understanding of such feedback loop is still limited. Before COVID-19 the literature on the subject was mainly theoretical and largely missed validation. The main issue was the lack of empirical data capturing behavioral change induced by diseases. Things have dramatically changed in 2020. Non-pharmaceutical interventions (NPIs) have been the key weapon against the SARS-CoV-2 virus and affected virtually any societal process. Travels bans, events cancellation, social distancing, curfews, and lockdowns have become unfortunately very familiar. The scale of the emergency, the ease of survey as well as crowdsourcing deployment guaranteed by the latest technology, several Data for Good programs developed by tech giants, major mobile phone providers, and other companies have allowed unprecedented access to data describing behavioral changes induced by the pandemic. Here, I review some of the vast literature written on the subject of NPIs during the COVID-19 pandemic. In doing so, I analyze 348 articles written by more than 2518 of authors in the first 12 months of the emergency. While the large majority of the sample was obtained by querying PubMed, it includes also a hand-curated list. Considering the focus, and methodology I have classified the sample into seven main categories: epidemic models, surveys, comments/perspectives, papers aiming to quantify the effects of NPIs, reviews, articles using data proxies to measure NPIs, and publicly available datasets describing NPIs. I summarize the methodology, data used, findings of the articles in each category and provide an outlook highlighting future challenges as well as opportunities.

show abstract

Section: Reviewsmentioning

confidence: 99%

“…Here, we find two reviews that highlight the incredible opportunities offered by digital technologies to capture behaviors, their changes and inform modeling as well as policies [364] , [365] . Interestingly, they also discuss the issues linked to privacy, legal, ethical concerns and biases in the data.…”

Section: Reviewsmentioning

confidence: 99%

Non-pharmaceutical interventions during the COVID-19 pandemic: A review

2021

View full text Add to dashboard Cite

show abstract

“…Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome (SARS)-like coronavirus 2 (SARS-CoV-2), has quickly spread across the world and become as a global health emergency (Boehmer et al 2020 ; Dirlikov et al 2020 ; Grantz et al 2020 ). The most common symptoms of COVID-19 include cough, fatigue, myalgia, sputum production, and shortness of breath, indicating that SARS-CoV-2 mainly affects the respiratory system and results in acute respiratory illness (Hauguel-Moreau et al 2020 ; Munro and Faust 2020 ; Nie et al 2020 ; Puccioni-Sohler et al 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Miller Fisher syndrome associated with COVID-19: an up-to-date systematic review

Shen

et al. 2021

Environ Sci Pollut Res

View full text Add to dashboard Cite

Recently, during the pandemic infection of the novel SARS-CoV-2, some cases of Miller Fisher syndrome (MFS) have been reported. We want to summarize the main features of patients with MFS and COVID-19. A PubMed search was performed on 8 October to identify references reporting cases with MFS associated with COVID-19 from the first report of COVID-19 to 8 October 2020 using the following keywords: “Miller Fisher syndrome” AND “COVID-19” OR “SARS-CoV-2”. A systematic review from the first report of coronavirus disease 2019 (COVID-19) to 8 October 2020 revealed 7 cases with Miller Fisher syndrome (MFS) associated with COVID-19. The 7 cases came from 5 countries but most of these patients were from Europe (85.7%), especially Spain. There are 5 cases of MFS diagnosed after the laboratory confirmation of SARS-CoV-2 infection. The mean onset time of MFS-associated neurological symptoms was 14.75 days after the diagnosis of COVID-19. However, the two remaining cases presented initially with MFS-associated neurological symptoms followed by the diagnosis of COVID-19. The most common symptoms of COVID-19-associated MFS were perioral paresthesias (57.1%), ataxia (57.1%), blurred vision (42.9), ophthalmoplegia (42.9), and generalized areflexia (42.9). However, more cohort and case-control studies are required to establish the epidemiological linkage.

show abstract

“…While mobility patterns can serve as a critical tool for assessing COVID-19 intervention impacts, there exists various challenges and limitations to their use. 4 Based on our most recent findings, parameterising SARS-CoV-2 transmission models using mobility data alone is likely to result in poorly performing models and inaccurate forecasts. The absence of a significant effect of mobility on SARS-CoV-2 transmission across all counties after April, even when accounting for outbreak magnitude and phase, suggests there are probably more critical factors than mobility alone for controlling COVID-19.…”

mentioning

confidence: 99%